Business Wire

RELX-TECHNOLOGY

Share
RELX Opens Bioscience Lab to Enhance Global E-Cigarette Research

RELX Technology today announced the company has started operations at its newly-established e-cigarette bioscience laboratory to conduct systematic research on the effects of e-cigarettes through in vivo and in vitro tests, as well as conduct pre-clinical safety assessments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200917005346/en/

The bioscience laboratory, located in International Bioindustry Valley, Shenzhen is currently conducting research on the impact of RELX products on animal cardiovascular, respiratory, and nervous systems, in order to better carry out a comprehensive impact evaluation of vapor products.

“Science is the foundation of trust. As the industry leader, we have the responsibility to expand the borders of e-cigarette science and explore the unknown,” said Kate Wang, founder and CEO of RELX.

At the RELX Lab Open Day, RELX also announced its plan to establish a “1+4” scientific research approach—i.e. anchored by Platform Development, followed by Toxicological Assessment, Clinical Assessment, Perception Behavior Study and Long Term Assessment.

According to Public Health England, e-cigarettes are 95% less harmful to health than smoking and have the potential to help smokers quit smoking. Many consumers have recognized e-cigarettes as a better alternative to traditional combustible cigarettes.

There are still many areas that require further long-term research, such as the actual harm reduction elements of e-cigarettes, the maximization of their harm reduction, and other potential effects of vaping.

“E-cigarettes are sometimes viewed with suspicion because we have incomplete knowledge,” said Yilong Wen, RELX Co-founder and Head of Science, Research and Development and Supply Chain, “The RELX bioscience lab’s mission is to explore the unknown. We want to collect evidence through a scientific approach and strive to prove the potential for e-cigarettes to be less harmful, and in doing so, provide users the option to choose an alternative.

To ensure the reliability and quality of RELX products, RELX established a chemical and physical laboratory in 2018. The laboratory is certified by the internationally recognized China National Accreditation Service for Conformity Assessment. RELX started its groundbreaking research on the toxicological and pharmacological study on its products in 2019, and the new bioscience lab will focus on vivo and in vitro tests, as well as conduct pre-clinical safety assessments in 2020.

“The toxicological and pharmacological studies focus on the effects of RELX’s products,” said Xingtao Jiang, Head of RELX Lab, “For example, does it affect DNA or chromosomes, and what are the ingredients’ long-term impact on body organs and tissues? There is still a lot of research to be done.”

Xingtao Jiang also announced five preliminary findings from RELX’s research so far. Among these were that according to the data, the levels of harmful substances such as benzene and four TSNAs (Tobacco-specific N-nitrosoamines) emitted by RELX products are lower than those found in combustible cigarette smoke by over 99.1 percent and 99.8 percent respectively.

RELX is currently conducting research projects on different topics with six universities including the Sun Yat-sen University and Shenzhen Institutes of Advanced Technology, the Chinese Academy of Sciences, two hospitals and nine scientific research institutions.

ABOUT RELX Technology

Founded in January 2018, RELX is Asia’s leading e-cigarette brand. RELX independently develops its e-cigarette products at its R&D center in Shenzhen, China. RELX’s mission is to empower adult smokers through technology, product and science, ethically. RELX continues to make significant investments in R&D, e-liquid testing and new product development. The company has attracted global talents from Uber, Proctor and Gamble, Huawei, Beats, and L’Oréal. RELX investors include top venture capital firms Source Code Capital, IDG Capital, and Sequoia Capital.

Website: https://relxnow.com
Twitter: @Relxtech
Facebook: @Relxnow
Instagram: relxtech
Linkedin: RELX Technology

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment17.9.2025 14:00:00 CEST | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the launch of a new brand, “Hada no Aozora Clinic”, scheduled to open in Tokyo on October 1, 2025. This clinic will adopt a hybrid dermatology model that integrates insurance-covered general dermatology and private-pay aesthetic treatments, advancing SBC’s multi-brand strategy in the rapidly expanding aesthetic medicine market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917897380/en/ SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment As life expectancy continues to rise and demographic aging accelerates, more people are seeking treatments that help them maintain both well-being and a youthful appearance over a longer lifespan. Within this environment, aesth

Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board17.9.2025 14:00:00 CEST | Press release

IND clearance marks second study accepted for RLS-1496, a first-in-class disease-modifying selective GPX4 modulator targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases and conditions associated with the biological aging process through ferroptosis Results from first RLS-1496 study in patients with psoriasis, atopic dermatitis, and skin aging are expected in Q4 2025; the actinic keratosis Phase 1b/2a study will begin in Q4 2025 Rubedo Clinical Advisory Board expands to include globally renowned dermatologist and immunologist Emma Guttman-Yassky, MD, PhD., Waldman Professor of Dermatology and Immunology and Health System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the U.S

New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs17.9.2025 14:00:00 CEST | Press release

Universal Surveillance Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ – Repeatedly Shown to Improve Patient Outcomes and Save Lives – Also Projected to Yield Significant Cost Savings Masimo (NASDAQ: MASI) today announced the findings of a study published in the Journal of Patient Safety in which Dr. George Blike and colleagues at Dartmouth-Hitchcock Medical Center in New Hampshire demonstrated that use of Masimo technologies to continuously monitor general floor patients can yield significant cost savings.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917266545/en/ Continuous Patient Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ In prior studies, the clinical outcome benefits of continuously monitoring patients using Masimo SET® and Patient SafetyNet™ have been shown to include lower mortality, improved resuscitative outcomes, and fewer rapid response team activations and transfers

Merck to Present New Data Highlighting Durable Effects of MAVENCLAD® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 202517.9.2025 14:00:00 CEST | Press release

Four-year data show nearly 9 in 10 RMS patients remained free from progression independent of relapse activity (PIRA)Results highlight the potential of MAVENCLAD to reduce neurodegeneration and neuroinflammation beyond established clinical efficacy outcomes in RMSEvidence suggests that MAVENCLAD effectiveness could be driven by peripheral and central effects without requiring continuous immunosuppression Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its multiple sclerosis (MS) portfolio. New four-year data from two large Phase 4 studies highlight the long-term efficacy, favorable disability outcomes and durable impact of MAVENCLAD® (cladribine tablets) in people living with relapsing multiple sclerosis (RMS). These findings are to be presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held September 24-26 in

Kinectrics Significantly Increases Isotope Production Capacity to Meet Growing Global Demand17.9.2025 13:30:00 CEST | Press release

Kinectrics, a division of BWX Technologies Inc. (NYSE: BWXT), announced today the completion of a major expansion to its isotope production capabilities, reinforcing its role as a global supplier of highly enriched stable isotopes and establishing the only North American source for Yb-176, reducing the reliance on foreign material for life-saving cancer treatments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917450864/en/ Travis Besanger, Kinectrics VP of Medical Isotopes, speaking within the new Isotope Separation Production Facility at Kinectrics Headquarters in Toronto, Canada. Kinectrics commissioned four new 2nd generation Electromagnetic Isotope Separator (EMIS) units, which will boost its annual production capacity to over 500 grams of Ytterbium-176 (Yb-176), the precursor for Lutetium-177 (Lu-177), by the end of the year. This scaled output will support over 150,000 patient treatments annually. Lu-177 is a medi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye